Monday November 23 2009 | Biotechnology feed | All feeds
|
|
Monday November 23 2009 | Biotechnology feed | All feeds
|
|
|
Angiogenesis inhibitors for the treatment of arthritis Inhibitors of angiogenesis represent one of the highest profile classes of therapeutic candidates to have been developed over the past two decades. This therapeutic class is anticipated to represent a major focus of anti-cancer therapy and consequently the commercial rewards for developing a successful anti-angiogenic compound are immense. Indeed by 2006, the market for all products that play a role in angiogenesis is predicted to reach $1.75 billion. Although the spotlight has been on cancer in relation to this class, a rapidly growing body of evidence suggests that arthritis could be successfully treated with inhibitors of angiogenesis. Increased angiogenesis is a key component of synovitis and bone modeling in arthritis. Molecular mechanisms and pathological consequences of blood vessel growth in arthritis are now being elucidated. Preclinical studies of angiogenesis inhibitors in animal models of inflammatory arthritis support the hypothesis that inhibition of neovascularization may reduce inflammation and joint damage. Thus, companies involved in inflammatory disease, musculoskeletal disorders or vascular pharmacology should consider the increasing potential of angiogenesis inhibitors. Link to journal abstract:
Adapted from Walsh & Haywood, Curr Opin Investig Drugs 2001 Aug;2(8):1054-63 Interested in collaborating with this group? Contact leaddiscovery@bioportfolio.co.uk LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|
